NCT00154388已完成2 期
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 185
- 主要终点
- To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases
研究概览
简要总结
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 15 years of age
- •Life threatening disease documented by conventional criteria to be resistant to standard, approved therapy.
- •Experimental documentation of functional significance of either Abl, Kit (CD117), or PDGF-R in the relevant target tissue (preferably on a sample taken within 6 weeks of study entry).
- •ECOG Performance status of 0, 1, or
- •Adequate end organ function defined as: total bilirubin < 1.5 x ULN, SGOT and SGPT < 2.5 x UNL (or < 5 x ULN for patients with hepatic disease), creatinine < 1.5 x ULN, ANC > 1.5 x 109/L, platelets > 100 x 109/L.
- •Negative serum or urine pregnancy test for women of child bearing potential (WOCBP) within 7 days of study initiation. Post menopausal women must have experienced amenorrhea for at least 12 months. Male and female patients must use effective birth control methods throughout the study and for up to 3 months after study discontinuation.
- •Life expectancy of more than 3 months.
- •Written, voluntary, informed consent for retrieval, evaluation and investigational use of tissue samples.
排除标准
- •Patients who have received any other investigational agent within 28 days of study initiation.
- •Patients with another primary malignancy except if other primary malignancy is neither currently clinically significant nor requiring active intervention.
- •Patients with Grade III/IV cardiac problems defined by the New York Heart Association Criteria (e.g. congestive heart failure, myocardial infarction within 6 months of study).
- •Female patients who are pregnant or breast-feeding.
- •Patients who have another severe and/or life threatening medical disease.
- •Patients with acute or known chronic liver disease (e.g. chronic active hepatitis, cirrhosis).
- •Patients with a known diagnosis of the human immunodeficiency virus ((HIV) infection.
- •Patients who have received chemotherapy within 4 weeks (6 weeks allowed for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry.
- •Patients who have had major surgery within 2 weeks prior to study entry.
- •Patients with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases
To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease
次要结局
- To assess the safety and tolerability of Imatinib mesylate
- To evaluate the pharmacokinetic profile of Imatinib mesylate
- To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues
研究者
相似试验
已完成
2 期
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansDermatofibrosarcoma ProtuberansAdult FibrosarcomaRecurrent Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaNCT00084630National Cancer Institute (NCI)40
已完成
2 期
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaPhiladelphia Chromosome Positive Acute Lymphocytic LeukemiaNCT00154349Novartis Pharmaceuticals8
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
已完成
2 期
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)Gastrointestinal Stromal TumorsNCT00237172Novartis Pharmaceuticals72
已完成
2 期
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)GliosarcomaGlioblastomaNCT00615927Duke University64